$ALDX
Aldeyra Therapeutics, Inc.

2020 Q4 Form 10-Q Financial Statement

#000156459020051290 Filed on November 05, 2020

View on sec.gov

Income Statement

Concept 2020 Q4 2020 Q3 2019 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.500M $2.260M $3.210M
YoY Change -22.12% -20.42% 25.88%
% of Gross Profit
Research & Development $7.030M $6.134M $9.610M
YoY Change -26.85% -62.19% 12.4%
% of Gross Profit
Depreciation & Amortization -$160.0K $80.00K $30.00K
YoY Change -633.33% 300.0% 50.0%
% of Gross Profit
Operating Expenses $9.540M $6.134M $12.83M
YoY Change -25.64% -62.19% 15.69%
Operating Profit -$8.389M
YoY Change -55.88%
Interest Expense -$480.0K $489.2K -$270.0K
YoY Change 77.78% 1577.95% -158.7%
% of Operating Profit
Other Income/Expense, Net -$484.0K
YoY Change -260.7%
Pretax Income -$11.77M -$8.873M -$13.16M
YoY Change -10.56% -52.59% 23.8%
Income Tax -$480.0K $0.00
% Of Pretax Income
Net Earnings -$11.29M -$8.873M -$13.16M
YoY Change -14.21% -52.59% 23.8%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$291.9K -$234.7K -$475.8K
COMMON SHARES
Basic Shares Outstanding 38.82M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q4 2020 Q3 2019 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $77.86M $86.20M $73.36M
YoY Change 6.13% 13.17% -21.62%
Cash & Equivalents $77.86M $86.18M $44.43M
Short-Term Investments $0.00 $0.00 $28.94M
Other Short-Term Assets $5.200M $2.000M $1.800M
YoY Change 188.89% 150.0% 50.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $83.06M $88.19M $75.17M
YoY Change 10.5% 14.51% -20.68%
LONG-TERM ASSETS
Property, Plant & Equipment $59.93K $79.46K $148.4K
YoY Change -59.63% -53.93% -36.89%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00
YoY Change -100.0%
Total Long-Term Assets $293.2K $131.7K $349.5K
YoY Change -16.09% -68.7% 8.57%
TOTAL ASSETS
Total Short-Term Assets $83.06M $88.19M $75.17M
Total Long-Term Assets $293.2K $131.7K $349.5K
Total Assets $83.35M $88.32M $75.52M
YoY Change 10.37% 14.05% -20.58%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $381.6K $123.9K $808.3K
YoY Change -52.79% -78.35% -73.51%
Accrued Expenses $8.135M $4.019M $11.87M
YoY Change -31.49% -64.52% 119.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $3.700M $2.300M
YoY Change
Total Short-Term Liabilities $12.41M $6.500M $12.91M
YoY Change -3.86% -46.35% 52.34%
LONG-TERM LIABILITIES
Long-Term Debt $11.43M $12.69M $14.53M
YoY Change -21.29% -11.77%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $11.43M $12.69M $14.53M
YoY Change -21.29% -11.77%
TOTAL LIABILITIES
Total Short-Term Liabilities $12.41M $6.500M $12.91M
Total Long-Term Liabilities $11.43M $12.69M $14.53M
Total Liabilities $23.84M $19.20M $27.44M
YoY Change -13.09% -27.72% 223.8%
SHAREHOLDERS EQUITY
Retained Earnings -$236.9M -$225.6M -$199.4M
YoY Change 18.84% 21.17% 43.91%
Common Stock $296.4M $247.4M
YoY Change 19.8% 9.89%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $59.51M $69.17M $48.08M
YoY Change
Total Liabilities & Shareholders Equity $83.35M $88.32M $75.52M
YoY Change 10.37% 14.05% -20.58%

Cashflow Statement

Concept 2020 Q4 2020 Q3 2019 Q4
OPERATING ACTIVITIES
Net Income -$11.29M -$8.873M -$13.16M
YoY Change -14.21% -52.59% 23.8%
Depreciation, Depletion And Amortization -$160.0K $80.00K $30.00K
YoY Change -633.33% 300.0% 50.0%
Cash From Operating Activities -$8.310M -$6.240M -$11.22M
YoY Change -25.94% -25.0% 40.78%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $5.500M -$4.280M
YoY Change -100.0% -3.0% -85.22%
Cash From Investing Activities $0.00 $5.500M -$4.280M
YoY Change -100.0% -3.0% -85.23%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 26.22M 8.340M
YoY Change -100.0% 76.68% -87.42%
NET CHANGE
Cash From Operating Activities -8.310M -6.240M -11.22M
Cash From Investing Activities 0.000 5.500M -4.280M
Cash From Financing Activities 0.000 26.22M 8.340M
Net Change In Cash -8.310M 25.48M -7.160M
YoY Change 16.06% 109.02% -124.4%
FREE CASH FLOW
Cash From Operating Activities -$8.310M -$6.240M -$11.22M
Capital Expenditures $0.00 $0.00 $0.00
Free Cash Flow -$8.310M -$6.240M -$11.22M
YoY Change -25.94% -25.0% 40.95%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y5M26D
aldx Line Of Credit Facility Interest Payment Period
LineOfCreditFacilityInterestPaymentPeriod
2021-05-01
aldx Line Of Credit Facility Interest Payment Extension Period
LineOfCreditFacilityInterestPaymentExtensionPeriod
2022-05-01
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y4M17D
CY2019Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
28938545
CY2020Q3 us-gaap Assets
Assets
88324430
dei City Area Code
CityAreaCode
781
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11873122
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
808302
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
201007
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
148449
CY2019Q4 us-gaap Assets
Assets
75518281
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1804450
CY2019Q4 us-gaap Assets Current
AssetsCurrent
75168825
dei Local Phone Number
LocalPhoneNumber
761-4904
dei Entity Shell Company
EntityShellCompany
false
dei Entity File Number
EntityFileNumber
001-36332
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02421
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2020Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2017273
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-1968197
CY2020Q3 us-gaap Assets Current
AssetsCurrent
88192780
CY2020Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
52195
CY2020Q3 aldx Cash And Money Market Funds
CashAndMoneyMarketFunds
71175507
CY2020Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
38820347
CY2020Q3 aldx Cash Equivalent Reverse Repurchase Agreement
CashEquivalentReverseRepurchaseAgreement
15000000
CY2020Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
79455
dei Entity Address Address Line1
EntityAddressAddressLine1
131 Hartwell Avenue
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 320
dei Entity Address City Or Town
EntityAddressCityOrTown
Lexington
CY2020Q3 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
2259417
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
123900
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2020Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4018635
CY2020Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
38631709
CY2020Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
38631709
CY2020Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
58720
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-225623548
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
69170447
CY2020Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
88324430
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6133580
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
40716543
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1058516
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
126966
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-5866
aldx Net Loss
NetLoss
-26261549
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.23
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
50879294
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
69170447
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
86617979
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6133990
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
720964
CY2019Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
14528212
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
194848
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
14990
aldx Net Loss
NetLoss
-47666208
CY2019Q3 aldx Acquired In Process Research And Development
AcquiredInProcessResearchAndDevelopment
-47102
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2255617
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-8389197
CY2020Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
5215
CY2020Q3 us-gaap Interest Expense
InterestExpense
489191
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-483976
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8873173
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1309973
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-8873173
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37796946
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-8873173
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-18715014
us-gaap Net Income Loss
NetIncomeLoss
-26261549
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
48082317
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
52789666
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1757479
CY2020Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
22446055
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
998097
CY2020Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
57077
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
69170447
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
67333370
us-gaap Net Income Loss
NetIncomeLoss
-47666208
CY2019Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
115688
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
51604203
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
44425830
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2152938
CY2019Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-7687
CY2019Q3 aldx Net Loss
NetLoss
-18715015
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
50879294
us-gaap Profit Loss
ProfitLoss
-26261549
CY2019Q4 us-gaap Us Government Securities At Carrying Value
USGovernmentSecuritiesAtCarryingValue
28932679
CY2019Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
28932679
us-gaap Profit Loss
ProfitLoss
-47666208
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
6500602
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-1309973
us-gaap Share Based Compensation
ShareBasedCompensation
5453520
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
47357472
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
41749677
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
4246731
us-gaap Share Based Compensation
ShareBasedCompensation
6133990
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
424516
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
59766
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
91231
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
474771
us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
217806
us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
72284
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
212823
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-404264
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-684402
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-3082081
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-8022095
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
5604224
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-29176258
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-33757903
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
9529
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
5776090
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
36860554
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
34800000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
59000000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
29023910
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
22762007
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
40716543
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
720964
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1058516
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
126966
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
194849
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
14450000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
123186
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
41902025
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
15242627
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
86175507
us-gaap Nature Of Operations
NatureOfOperations
<div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.</span></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">NATURE OF BUSINESS </p></td></tr></table></div> <p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Aldeyra Therapeutics, Inc., together with its wholly-owned subsidiaries (the “Company” or “Aldeyra”), a Delaware corporation, is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. </p> <p style="margin-bottom:0pt;margin-top:12pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s principal activities to date include raising capital and research and development activities. </p>
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.53%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions, including fair value estimates for investments that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting periods. The Company’s management evaluates its estimates and assumptions on an ongoing basis. Management’s most significant estimates in the Company’s consolidated financial statements include, but are not limited to, estimates related to clinical trial accruals, estimates related to prepaid and accrued research and development costs, acquired in-process research and development (“IPR&amp;D”) expense, contingent liabilities, and accounting for income taxes and related valuation allowance. Although these estimates and assumptions are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions. </p>
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6008140
CY2020Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6008140
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5396176
CY2019Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5396176
CY2020Q3 us-gaap Cash
Cash
31815216
CY2020Q3 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
39360291
CY2020Q3 aldx Cash Equivalent Reverse Repurchase Agreement
CashEquivalentReverseRepurchaseAgreement
15000000
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
86175507
CY2020Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
86175507
CY2019Q4 us-gaap Cash
Cash
15363462
CY2019Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
1062368
CY2019Q4 aldx Cash Equivalent Reverse Repurchase Agreement
CashEquivalentReverseRepurchaseAgreement
28000000
CY2019Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
44425830
CY2019Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
28938545
CY2020Q3 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
0
CY2019Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
0
CY2020Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1328475
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1489475
CY2020Q3 aldx Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
1960150
CY2019Q4 aldx Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
9493093
CY2020Q3 aldx Accrued General And Administrative Expense Current
AccruedGeneralAndAdministrativeExpenseCurrent
730010
CY2019Q4 aldx Accrued General And Administrative Expense Current
AccruedGeneralAndAdministrativeExpenseCurrent
890554
CY2020Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4018635
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11873122
us-gaap Line Of Credit Facility Interest Rate During Period
LineOfCreditFacilityInterestRateDuringPeriod
0.0910
us-gaap Line Of Credit Facility Expiration Date1
LineOfCreditFacilityExpirationDate1
2023-10-01
aldx Line Of Credit Facility Commitment Charge
LineOfCreditFacilityCommitmentCharge
25000
aldx Line Of Credit Facility Transaction Costs
LineOfCreditFacilityTransactionCosts
273186
us-gaap Line Of Credit Facility Commitment Fee Amount
LineOfCreditFacilityCommitmentFeeAmount
375000
us-gaap Line Of Credit Facility Commitment Fee Percentage
LineOfCreditFacilityCommitmentFeePercentage
0.0695
CY2020Q3 us-gaap Line Of Credit Facility Interest Rate At Period End
LineOfCreditFacilityInterestRateAtPeriodEnd
0.129
us-gaap Line Of Credit Facility Description
LineOfCreditFacilityDescription
3% if the term loan is prepaid prior to March 25, 2021 and 1.5% if the term loan is prepaid any time thereafter, but prior to March 25, 2022
CY2020Q3 us-gaap Long Term Loans Payable
LongTermLoansPayable
15000000
CY2019Q4 us-gaap Long Term Loans Payable
LongTermLoansPayable
15000000
CY2020Q3 aldx End Of Term Charge
EndOfTermCharge
356372
CY2019Q4 aldx End Of Term Charge
EndOfTermCharge
89094
CY2020Q3 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
403644
CY2019Q4 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
560881
CY2020Q3 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
2259417
CY2020Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
12693311
CY2019Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
14528212
CY2019Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
3659776
CY2019Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
5931718
CY2019Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
6451006
CY2019Q4 us-gaap Long Term Debt
LongTermDebt
16042500
aldx Deferred Tax Assets Valuation Allowance Percentage
DeferredTaxAssetsValuationAllowancePercentage
1
CY2020Q3 aldx Deferred Tax Assets Operating Loss Carryforwards Subject To Limitation
DeferredTaxAssetsOperatingLossCarryforwardsSubjectToLimitation
9000000
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
58720
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2745371
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
5.95
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
9439040
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1757479
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2152938
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5453520
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6133990
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4193814
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.62
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1669023
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.91
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
219244
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
4.83
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
75838
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
6.72
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
678070
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
6.53
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4889685
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.79
CY2020Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
4924800
CY2020Q3 us-gaap Share Price
SharePrice
7.41
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
58700
CY2020Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.091
CY2020Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P0Y3M
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
59613
us-gaap Operating Lease Expense
OperatingLeaseExpense
200000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
59613
CY2020Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
893
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
58720
CY2020Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
58720
CY2020Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
59613

Files In Submission

Name View Source Status
0001564590-20-051290-index-headers.html Edgar Link pending
0001564590-20-051290-index.html Edgar Link pending
0001564590-20-051290.txt Edgar Link pending
0001564590-20-051290-xbrl.zip Edgar Link pending
aldx-10q_20200930.htm Edgar Link pending
aldx-10q_20200930_htm.xml Edgar Link completed
aldx-20200930.xsd Edgar Link pending
aldx-20200930_cal.xml Edgar Link unprocessable
aldx-20200930_def.xml Edgar Link unprocessable
aldx-20200930_lab.xml Edgar Link unprocessable
aldx-20200930_pre.xml Edgar Link unprocessable
aldx-ex1033_26.htm Edgar Link pending
aldx-ex311_7.htm Edgar Link pending
aldx-ex312_6.htm Edgar Link pending
aldx-ex321_8.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending